Tirzepatide (15mg Vial) Dosage Protocol
Tirzepatide is a dual GLP-1/GIP receptor agonist — it activates both incretin receptors to enhance glucose-dependent insulin release, suppress glucagon, slow gastric emptying and reduce appetite. In clinical trials it produced some of the largest weight-loss and glycemic results of any incretin therapy, with a long half-life that supports a single weekly subcutaneous injection and a stepwise titration that keeps gastrointestinal effects manageable.
Mix & measure Tirzepatide · 15 mg
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →
Quickstart Highlights
Tirzepatide is a dual GLP-1/GIP receptor agonist — it engages two incretin pathways to curb appetite and improve glycemic control[1] — and has been studied for substantial weight loss and broad metabolic improvement in obesity and type 2 diabetes[2][3]. A long half-life of roughly 6 days makes a single weekly subcutaneous injection practical, while gradual titration keeps tolerability high from the first dose[1][4].
Add 2.0 mL bacteriostatic water to one 15 mg vial → final concentration: 7.5 mg/mL.
2.5–15 mg once weekly (gradual 4-week titration).
At 7.5 mg/mL, 1 mg = 0.13 mL = 13 units on a U-100 insulin syringe.
Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.
Important: Read the Prep & Injection Guide first — it covers the preparation and safety basics that every protocol on this site assumes.
Dosing & Reconstitution Guide
Reconstitution and accurate weekly dosing, step by step
Standard / Gradual Titration Approach (2 mL = 7.5 mg/mL)
Reconstitute: Add 2.0 mL bacteriostatic water to one 15 mg vial → final concentration: 7.5 mg/mL.
Typical weekly range: 2.5–15 mg once weekly (gradual 4-week titration).
Easy measuring: At 7.5 mg/mL, 1 mg = 0.13 mL = 13 units on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.
Frequency: one subcutaneous injection each week. The schedule mirrors the clinical-trial protocols that drove substantial weight loss — around 20% of body weight over 72 weeks on the 15 mg dose[2] — while holding gastrointestinal effects down through gradual escalation[1][4]. Opening at 2 mg weekly rather than 4 mg markedly softens early GI effects, and any higher weekly dose simply calls for more than one vial or a split across two sites.
Reconstitution Steps
Pull 2.0 mL of bacteriostatic water into a sterile syringe.
Release it slowly against the vial’s inner wall to avoid foaming.
Swirl or roll gently until fully dissolved — don’t shake hard.
Note the mixing date and store at 2–8 °C (35.6–46.4 °F), shielded from light.
At 7.5 mg/mL, doses up to 7.5 mg fit within a single U-100 syringe; the 10 mg dose is split into two ~0.67 mL injections. Use additional vials as the dose climbs.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Quantities below assume a 12–48 week course of weekly injections, titrated gradually up to the maintenance dose.
Vial use scales with the weekly titration schedule.
- 8 weeks (2.5→5 mg/wk): ~2 vials
- 12 weeks (2.5→7.5 mg/wk): ~4 vials
- 16 weeks (2.5→10 mg/wk): ~7 vials
- Per week: 1 syringe (once-weekly dosing)
- 12 weeks: 12 syringes
- 24 weeks: 24 syringes
- 48 weeks: 48 syringes
Use 2.0 mL per vial for reconstitution.
- 8 weeks (2 vials): 4 mL → 1 × 10 mL bottle
- 12 weeks (4 vials): 8 mL → 1 × 10 mL bottle
- 16 weeks (7 vials): 14 mL → 2 × 10 mL bottles
One for the vial stopper + one for the injection site each week.
- Per week: 2 swabs
- 12 weeks: 24 swabs → 1 × 100-count box
- 24 weeks: 48 swabs → 1 × 100-count box
- 48 weeks: 96 swabs → 1 × 100-count box
Protocol Overview
The once-weekly regimen at a glance, drawn from the clinical-trial protocols.
- ▪Goal: Drive substantial weight loss (up to ~20% of body weight) and stronger metabolic markers through dual GLP-1/GIP receptor agonism[2][5].
- ▪Schedule: One subcutaneous injection a week for 12+ weeks, with the dose raised gradually.
- ▪Dose Range: 2.5–15 mg weekly, titrated in 2.5 mg steps every 4 weeks[1][3].
- ▪Reconstitution: 2.0 mL bacteriostatic water per 15 mg vial produces 7.5 mg/mL — handy for precise 2.5–15 mg steps.
- ▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.
Dosing Protocol
The week-by-week titration, mapped to the clinical-trial dosing.
- ▪Start: 2.5 mg weekly for the first 4 weeks to settle tolerability[1][4].
- ▪Escalation: Step up to 5 mg for Weeks 5–8, then 7.5 mg for Weeks 9–12[1].
- ▪Maintenance: 10 mg weekly from Week 13; some protocols titrate further to 12.5–15 mg if well tolerated[2].
- ▪Frequency: Once a week, subcutaneous — holding the same day and time each week aids consistency.
- ▪Cycle Length: Roughly 16–20 weeks to finish escalation; trials ran to 72 weeks with continued, progressive weight loss[2].
- ▪Timing: Any steady weekly schedule works; change the injection site with each dose.
Storage Instructions
Correct storage is what preserves the peptide’s stability and potency.
- ▪Lyophilized: Hold at −20 °C (−4 °F) or colder for long-term keeping; shield from moisture and light[11][12].
- ▪Reconstituted: Chill at 2–8 °C (35.6–46.4 °F) as soon as it’s mixed and use within 2–4 weeks to keep stability and potency[11].
- ▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form; keep the mixed solution clear of heat and direct sun.
- ▪Aliquoting: To store beyond 4 weeks, divide the unused portion into aliquots and freeze; steer clear of repeated freeze–thaw cycles, which cause degradation[12].
Important Notes
Practical points that keep weekly administration safe and consistent.
- ▪Weekly consistency: Lock in one day and time for the weekly injection and keep to it for the whole protocol.
- ▪Gradual titration is essential: Opening at 2 mg weekly instead of a higher dose markedly lowers the odds of early gastrointestinal effects[4].
- ▪Syringe use: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward[14].
- ▪Injection site rotation: Move sites week to week (abdomen, thighs, upper arms), keeping each shot at least 1 inch from the last to limit irritation and prevent lipohypertrophy[15].
- ▪Large volumes: When a dose needs more than 1.0 mL (>100 units), divide it across sites or draw from more than one reconstituted vial.
- ▪Side-effect monitoring: Mild nausea or stomach upset is normal while escalating; if it becomes notable, hold the current dose longer before stepping up.
How This Works
Tirzepatide is a dual GLP-1/GIP receptor agonist: it activates both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) incretin receptors, which together regulate appetite, glucose-dependent insulin release and glucagon[1][5]. These complementary receptor actions reduce appetite and energy intake, slow gastric emptying, and improve glucose regulation, which together drive steady weight loss.
GLP-1-receptor activation curbs appetite, slows gastric emptying and boosts glucose-dependent insulin release — together these cut food intake and steady blood sugar[5][8]. Together, they add up to a profound metabolic effect.
With an extended half-life of ~6 days, a single weekly dose holds therapeutic levels steady between injections[1].
In trials, participants on the highest weekly doses lost on average around 20% of body weight over 72 weeks[2]. In adults with type 2 diabetes, the higher doses produced strong weight loss alongside HbA1c reductions of up to ~2.4% versus placebo[3].
In the SURMOUNT-1 phase-3 trial, tirzepatide produced dose-dependent weight loss reaching about ~21% of total body weight at the 15 mg dose, substantially more than placebo, with gastrointestinal symptoms the most common adverse events[6][7].
Lifestyle Factors
Habits that work alongside the protocol to protect results and ease the transition.
- ▪Nutrition: Eat a balanced, protein-forward diet (1.0–1.2 g/kg body weight) to hold on to lean mass while losing weight[10].
- ▪Hydration: Keep fluids up, particularly while titrating, when GI effects peak.
- ▪Physical activity: Pair resistance training (2–3×/week) with moderate cardio to aid metabolic adaptation and protect muscle.
- ▪Sleep & stress: Aim for 7–9 hours of solid sleep and manage stress to support hormonal balance and stay on track.
- ▪Meal timing: Smaller, more frequent meals help some people handle GI effects during early titration.
Potential Benefits & Side Effects
What human phase 2 and phase 3 trials have reported.
Potential Benefits
- ▪Substantial weight loss: Around 20% body-weight reduction by 72 weeks on the 15 mg dose[2].
- ▪Glycemic improvement: Marked HbA1c drops (about 2.0%) in adults with type 2 diabetes[3].
- ▪Metabolic benefits: Gains in lipid profile, blood pressure, and cardiovascular risk markers[1][5].
- ▪Convenient dosing: A single weekly subcutaneous dose is easier to stick with than daily regimens[1].
Common Side Effects
- ▪Gastrointestinal effects: Nausea, diarrhea, vomiting, and constipation top the list of adverse events; usually mild-to-moderate and easing with time[2][4].
- ▪Beginning at 2 mg weekly rather than 4 mg sharply cuts early GI events[4].
- ▪Injection site reactions: Mild redness, swelling, or soreness can show up at the site; rotating sites keeps it minimal.
- ▪Overall safety profile: Pooled trial data showed no meaningful rise in overall adverse events versus placebo[6][7].
Injection Technique
Subcutaneous injection technique, following established clinical practice and CDC guidance[13][14].
Pre-Injection Preparation
- ▪Wash your hands well with soap and water[14].
- ▪Wipe the vial stopper with an alcohol swab and let it air-dry.
- ▪Pick a site (abdomen, thigh, or upper arm) and wipe it with a fresh alcohol swab, letting it dry fully[13].
- ▪Carefully draw the intended dose, then check for air bubbles and push any out.
Injection Procedure
- ▪Pinch about a 1-inch fold of skin between thumb and forefinger[15].
- ▪Insert the needle into the pinch at a 90-degree angle (45 degrees if the fat layer is thin)[13][14].
- ▪Skip aspiration for subcutaneous shots — it isn’t needed and can add discomfort[13].
- ▪Press the plunger slowly and steadily until it’s fully down.
- ▪Pull the needle straight out and, if needed, press lightly with clean gauze.
Post-Injection Care
- ▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle[14].
- ▪Put the reconstituted vial back in the fridge right away.
- ▪Shift the site each week (at least 1 inch over) to prevent lipohypertrophy[15].
- ▪Watch the site for excess redness, swelling, or signs of infection.
Recommended Source
For high-purity Tirzepatide (15 mg vials), we point researchers to Prime Lab Peptides.
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
References
-
1
New England Journal of Medicine (2023)Once-Weekly Tirzepatide for Weight Management (SURMOUNT program; 72-week results)
-
2
JAMA Network (2023)Tirzepatide (SURMOUNT) obesity trials: efficacy and safety data (~20% weight loss at 15 mg weekly)
-
3
The Lancet (2023)Tirzepatide in type 2 diabetes: Phase 2 trial (weight loss and glycemic outcomes at 36 weeks)
-
4
PubMed / NEJM (2023)Tirzepatide dosing and tolerability: starting at 2 mg vs 4 mg reduces GI adverse events
-
5
Metabolites (PMC, 2025)Tirzepatide—A Game Changer in Obesity Pharmacotherapy (comprehensive review of mechanism and trials)
-
6
New England Journal of Medicine (2022)Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1, NEJM 2022)
-
7
PubMed (2025)Meta-analysis: Tirzepatide achieves ~14% greater weight reduction vs placebo with no increase in adverse events
-
8
Molecular Metabolism (2025)Preclinical tri-agonist NN1706 (related compound): mechanism and pharmacokinetics
-
9
Nature Reviews Endocrinology (2024)Dual GIP/GLP-1 receptor agonists for obesity and diabetes: a clinical landscape review
-
10
Journal of Cachexia, Sarcopenia and Muscle (PMC)Protein requirements during weight loss: preserving lean mass
-
11
GenScriptPeptide Storage and Handling Guidelines (technical bulletin for lyophilized and reconstituted peptides)
-
12
BachemHandling and Storage Guidelines for Peptides (technical article on stability and freeze-thaw cycles)
-
13
Centers for Disease Control and Prevention (CDC)Vaccine Administration: Subcutaneous Injection (technique, angle, and site guidance)
-
14
NCBI BookshelfInjection Administration Best Practices (aseptic technique, sharps disposal, and safety)
-
15
Pharmacologic Considerations of the Subcutaneous Route (PMC)Subcutaneous injection technique and site rotation to prevent lipohypertrophy
-
16
Prime Lab PeptidesTirzepatide (15 mg) product page (quality documentation and specifications)
How to reconstitute Tirzepatide
- 1Wipe the vial stopper and your bacteriostatic-water vial with an alcohol swab.
- 2Draw your chosen amount of bacteriostatic water and inject it slowly down the inner wall of the Tirzepatide vial.
- 3Let it rest, then gently swirl until fully dissolved — do not shake.
- 4Refrigerate the reconstituted vial and draw each dose with a U-100 insulin syringe.
Tirzepatide — frequently asked questions
How do I reconstitute a 15 mg vial of Tirzepatide?
Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.
How much bacteriostatic water should I add to Tirzepatide?
There is no single correct amount — more water simply spreads the same 15 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.
What do the "units" on an insulin syringe mean?
On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.
How should I store Tirzepatide after mixing?
Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.
How many doses does a 15 mg vial of Tirzepatide provide?
Divide the vial strength of 15 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.
Is Tirzepatide approved for human use?
No. Tirzepatide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.